• Dimethyloxalylglycine (DMOG): Technical Use and Protocol Gui

  2026-04-30

  Dimethyloxalylglycine (DMOG) is a cell-permeable inhibitor designed to stabilize hypoxia-inducible factor (HIF) in vitro and in vivo, supporting controlled hypoxia signaling studies and immune regulation workflows. It should be used in basic research settings and is not suitable for diagnostic or therapeutic applications due to its specificity and storage limitations.

• 5-hme-dCTP: Enabling Precision DNA Hydroxymethylation Assays

  2026-04-29

  5-hme-dCTP empowers plant scientists to map and manipulate 5-hydroxymethylcytosine with unmatched single-base resolution, driving advances in epigenetic DNA modification research. By integrating this high-purity nucleotide analog into workflows, researchers overcome prior detection limits and gain actionable insight into gene expression regulation under stress.

• AIBP-LRP2–Mediated HDL Uptake Restricts Capillary Expansion

  2026-04-29

  This study uncovers a two-phase mechanism by which AIBP-LRP2–mediated HDL uptake restricts the expansion of CXCR4+ stemlike capillary endothelial cells and thereby limits collateral circulation in ischemic disease. The findings provide a molecular framework for targeting vascular remodeling and suggest new strategies for therapeutic revascularization in conditions such as peripheral artery disease.

• hsa_circ_0136666 Drives Gastric Cancer Progression via miR-3

  2026-04-28

  Miao et al. (2023) establish that hsa_circ_0136666 promotes gastric cancer proliferation and tumor immune escape by modulating the miR-375/PRKDC axis and enhancing PD-L1 phosphorylation. Their work uncovers a novel immune evasion mechanism and suggests new therapeutic targets for gastric cancer intervention.

• Dacarbazine in Precision Oncology: DNA Damage Dynamics and A

  2026-04-28

  Explore how Dacarbazine, a leading antineoplastic chemotherapy drug, shapes cancer cell fate through intricate DNA damage pathways. This article delivers advanced insight into drug response measurement and protocol design, bridging foundational mechanism with translational assay strategy.

• Dimethyloxalylglycine (DMOG): Technical Use and Protocols

  2026-04-27

  Dimethyloxalylglycine (DMOG) is a cell-permeable, competitive inhibitor for controlled stabilization of hypoxia-inducible factor (HIF) in research models. It enables reproducible induction of hypoxia pathways and immune modulation in vitro and in vivo, but should not be used for diagnostic or clinical applications. Strict adherence to solubility and storage protocols is required for reliable results.

• CDK9 Inhibitor (A3294): Technical Use and Protocol Guidance

  2026-04-27

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for research on transcription elongation and HIV-1 propagation inhibition. It is suitable for applications requiring high specificity for CDK9 over other CDK family members, but not for studies needing broad-spectrum CDK inhibition or long-term storage of working solutions.

• Reelin Signaling Determines Ketamine’s Synaptic and Behavior

  2026-04-26

  This study reveals that intact synaptic Reelin signaling is essential for ketamine’s rapid antidepressant effects and associated hippocampal synaptic plasticity. By dissecting genetic and pharmacological disruptions in the Reelin-Apoer2-SFK axis, the research identifies key molecular determinants underlying nonresponsiveness to ketamine, with implications for treatment-resistant depression.

• BMS-777607: Catalyzing New Frontiers in Translational Resear

  2026-04-25

  This thought-leadership article explores the mechanistic and strategic value of BMS-777607 as a c-Met inhibitor, examining its role in oncology and stem cell research. By integrating robust evidence, protocol recommendations, and a forward-looking perspective, the discussion highlights how APExBIO's BMS-777607 empowers translational researchers to innovate in cancer metastasis models, optimize platelet biomanufacturing, and set new standards for experimental rigor.

• InstaBlue Protein Stain Solution: Rapid Coomassie Gel Staini

  2026-04-24

  InstaBlue Protein Stain Solution provides fast, sensitive protein visualization in polyacrylamide gels without fixation or destaining, streamlining protein electrophoresis analysis for biomedical research. It is not intended for use with membranes or non-polyacrylamide matrices, and applications outside standard protein gel staining should be validated independently.

• LDN-193189: Precision ALK Inhibitor Workflows for BMP Pathwa

  2026-04-24

  LDN-193189 stands out as a potent ALK inhibitor for targeted BMP signaling pathway inhibition, enabling robust epithelial barrier function studies and regenerative medicine breakthroughs. This guide translates the latest evidence into actionable protocols and troubleshooting strategies for maximizing research reproducibility with APExBIO’s benchmark inhibitor.

• Ethacridine Lactate Monohydrate: Epigenetic Assays & Antisep

  2026-04-23

  Explore the unique role of Ethacridine lactate monohydrate in advanced epigenetic and differentiation assays. This article reveals how its molecular properties and antiseptic mechanism enable precise microbial control for cutting-edge chromatin research.

• Ibrexafungerp Efficacy Against Echinocandin-Resistant Candid

  2026-04-23

  This study systematically examines the in vitro activity of ibrexafungerp (MK 3118) against a large cohort of echinocandin-resistant Candida isolates, focusing on the impact of specific FKS gene mutations. The findings clarify differential susceptibility patterns and highlight ibrexafungerp’s potential as an oral antifungal option for resistant Candida infections.

• Optimizing Cancer Assays with YC-1 (5-(1-benzyl-1H-indazol-3

  2026-04-22

  This article provides an expert-driven, scenario-based guide to deploying YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol (SKU B7641) in cell viability, proliferation, and cytotoxicity assays. Emphasizing reproducibility and sensitivity, it details how APExBIO’s high-purity YC-1 addresses common workflow challenges, supporting reliable cancer biology research.

• Olaparib (AZD2281): Innovations in Localized Cancer Therapy

  2026-04-22

  Explore how Olaparib (AZD2281) is revolutionizing BRCA-associated cancer research through advanced localized delivery strategies and nanoparticle technology. Gain actionable insight into tumor radiosensitization and DNA damage response assays, with unique protocol recommendations.

16416 records 1/1095 page Next 12345 下5页 Last page